- |||||||||| Journal: The mononuclear phagocyte system obscures the accurate diagnosis of infected joint replacements. (Pubmed Central) - Nov 20, 2024
However, the state of the MPS is of critical importance to accurate diagnosis of an implant-associated infection. A reduction in neutrophil recruitment and function mediated by the MPS may allow joint replacements with a dormant infection to be mischaracterized as uninfected, thus limiting the prognostic capabilities of all current diagnostic tests.
- |||||||||| Immunoglobulin Replacement Therapy (IgRT) for the Treatment of Haematological Malignancy Associated Secondary Immunodeficiency (HM-SID) (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4797;
A large proportion of patients at our centre treated since January 2021 had a history of prior treatment with CART or TCE, suggesting an emergent patient population at risk of HM-SID requiring treatment. Randomised control trial data is needed to accurately quantify the benefit of IgRT in the reduction of bacterial infection burden and the effect on patient reported outcomes, particularly in the context of those treated with immunotherapy.
- |||||||||| cemacabtagene ansegedleucel (ALLO-501A) / Allogene Therap
Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clones (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3684;
P1/2
We identified patients with relapsed/refractory large B-cell lymphoma treated on the ALPHA-2 phase 1 trial (NCT04416984) with a single lot of ALLO-501A, a healthy donor-derived CD19 CAR T with T cell receptor (TCR) and CD52 knockout using Cellectis technologies...Moreover, our data highlight clones with effector-like molecular states as a key subset which could mediate antitumor responses to allogeneic CAR T cell products. These findings, as well as the presence of this phenotype in donor PBMCs prior to manufacturing, carry important implications for future development of these therapies.
- |||||||||| Journal: Isolation of CD63-positive epididymosomes from human semen and its application in improving sperm function. (Pubmed Central) - Oct 17, 2024
Then, CD63-positive epididymosomes were isolated from human semen using a flow cytometry sorting instrument and concentrated. Additionally, we observed that isolated CD63-positive epididymosomes improved sperm function more than other CD63-positive seminal EV subpopulations did, demonstrating the successful isolation of a subpopulation of epididymosomes from human semen and their potential application in the clinic.
- |||||||||| Review, Journal, IO biomarker: Universal CAR cell therapy: Challenges and expanding applications. (Pubmed Central) - Oct 17, 2024
In addition, the limited efficacy of T cells and NK cells against solid tumors is being addressed through CAR-Macrophages. In summary, CAR cell therapy has evolved to accommodate multiple cell types while expanding applications to various diseases, including hematologic malignancies and solid tumors, which holds tremendous growth potential and is promised to improve the lives of more patients in the future.
- |||||||||| Journal: Flow cytometry as an alternative to microscopy for the differentiation of bronchoalveolar lavage fluid leukocytes. (Pubmed Central) - Oct 10, 2024
Together, these data demonstrate the ability to identify Pf-responsive T cells in CBMC using modern, robust, single cell approaches and suggest the potential for differential function of these cells by MMc status. We report, to our knowledge, the first validated flow cytometric method for BALF leukocyte differentiation, which can be used in clinical settings where local expertise for microscopic analysis is unavailable and which can be combined easily with lymphocyte surface marker analysis.
- |||||||||| Journal, IO biomarker: Optimizing Drug Combinations for T-PLL: Restoring DNA Damage and P53-Mediated Apoptotic Responses. (Pubmed Central) - Oct 10, 2024
We report, to our knowledge, the first validated flow cytometric method for BALF leukocyte differentiation, which can be used in clinical settings where local expertise for microscopic analysis is unavailable and which can be combined easily with lymphocyte surface marker analysis. Current treatments, that is, the CD52-antibody alemtuzumab, offer transient responses, with relapses being almost inevitable without consolidating allogeneic transplantation...Overall, the most efficient/selective single agents and combinations (in
- |||||||||| PHST001 / Pheast Therap
PHST001, a humanized anti-CD24 antibody, induces phagocytosis of human tumor cells in vitro and tumor clearance in vivo (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_881;
PHST001 does not induce cytokine release in vitro and detects CD24 in human tissues. A clinical study to investigate the safety and efficacy of PHST001 in cancer patients is being developed.Download figure Open in new tab Download powerpoint Abstract 513 Figure 1 Download figure Open in new tab Download powerpoint Abstract 513 Figure 2 Download figure Open in new tab Download powerpoint Abstract 513 Figure 3 Download figure Open in new tab Download powerpoint Abstract 513 Figure 4 Download figure Open in new tab Download powerpoint Abstract 513 Figure 5 Download figure Open in new tab Download powerpoint Abstract 513 Figure 6
- |||||||||| ALLO-316 / Allogene Therap
ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_376;
P1
A clinical study to investigate the safety and efficacy of PHST001 in cancer patients is being developed.Download figure Open in new tab Download powerpoint Abstract 513 Figure 1 Download figure Open in new tab Download powerpoint Abstract 513 Figure 2 Download figure Open in new tab Download powerpoint Abstract 513 Figure 3 Download figure Open in new tab Download powerpoint Abstract 513 Figure 4 Download figure Open in new tab Download powerpoint Abstract 513 Figure 5 Download figure Open in new tab Download powerpoint Abstract 513 Figure 6 Escalating doses of ALLO-316 (40
- |||||||||| Mayzent (siponimod) / Novartis, Lemtrada (alemtuzumab) / Sanofi
Journal: Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series. (Pubmed Central) - Sep 12, 2024
In conclusion, the long-term management of patients treated with Alemtuzumab transitioning to secondary progressive MS requires a proactive and multidisciplinary approach. By addressing the challenges associated with treatment limitations and short-term monitoring recommendations while considering alternative therapeutic options like Siponimod, clinicians can optimize outcomes and ensure continuity of care for individuals with MS.
- |||||||||| Campath (alemtuzumab) / Sanofi
Review, Journal: Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature. (Pubmed Central) - Sep 4, 2024
Despite known potential cardiotoxicity, the patient was treated with the anti-CD52 antibody alemtuzumab with a gradual dose increase from 3?mg to 30?mg per day...The reported case shows that T-PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.
- |||||||||| dasatinib / Generic mfg.
Journal, IO biomarker: T-cell dysfunction in CLL is mediated through expression of SIGLEC-10 ligands CD24 and CD52 on CLL cells. (Pubmed Central) - Aug 31, 2024
Inhibition of kinases involved in the CD40 signaling cascade revealed that the Spare Respiratory Capacity (SRC) kinase inhibitor dasatinib prevented rescue of T-cell function independent of CD40-mediated increased levels of costimulatory and adhesion ligands on CLL cells...These results demonstrate that T cells derived from CLL patients can be reinvigorated by manipulating CLL-T cell interactions. Targeting CD24- and CD52-mediated CLL-T cell interaction could be a promising therapeutic strategy to enhance T-cell function in CLL.
- |||||||||| Biomarker, Journal, IO biomarker, Machine learning, Immune cell: Identification of diagnostic biomarkers of rheumatoid arthritis based on machine learning-assisted comprehensive bioinformatics and its correlation with immune cells. (Pubmed Central) - Aug 22, 2024
The results of novel characteristic gene analysis of RA showed that KYNU, EVI2A, CD52, C1QB, BATF, AIM2 and NDC80 had good diagnostic and clinical value for the diagnosis of RA, and were closely related to immune cells. Therefore, these seven DEGs may become new diagnostic markers and immunotherapy markers for RA.
- |||||||||| Lemtrada (alemtuzumab) / Sanofi
CD52 mRNA expression in melanoma (ePoster Self-Study 1) - Jul 11, 2024 - Abstract #ADO2024ADO_12;
CD52 expression is associated with features of ICB response in melanoma. Concurrent anti-CD52 therapy and ICB should be critically evaluated.
- |||||||||| Campath (alemtuzumab) / Sanofi
Journal, CAR T-Cell Therapy: Umbilical cord blood T cells can be isolated and enriched by CD62L selection for use in 'off the shelf' chimeric antigen receptor T-cell therapies to widen transplant options. (Pubmed Central) - Jul 11, 2024
This provided stringent mitigation against the risk of graft versus host disease (GVHD), and was combined with simultaneous knockout of CD52 to enable persistence of edited T cells in combination with preparative lymphodepletion using Alemtuzumab...Molecular characterisation captured vector integration sites and CRISPR editing signatures and functional studies, including in vivo potency studies in humanised mice, confirmed antileukaemic activity comparable to peripheral blood-derived universal CAR19 T cells. Machine manufactured UCB derived T cells banks offer an alternative to autologous cell therapies and could help widen access to CAR T cells.
- |||||||||| Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Campath (alemtuzumab) / Sanofi, Adcetris (brentuximab vedotin) / Takeda, Pfizer
The Promise of Immunotherapies in T-Cell Lymphoma (Level 3, 370 C) - Jul 5, 2024 - Abstract #SOHO2024SOHO_15;
Machine manufactured UCB derived T cells banks offer an alternative to autologous cell therapies and could help widen access to CAR T cells. As of now, two
- |||||||||| Soluble CD52 suppresses hepatic chronic inflammation in obese mice (Sydney Hall) - Jul 1, 2024 - Abstract #EASD2024EASD_896;
CD52 appears to be a suppressor of hepatic chronic inflammation in obesity. Mechanistically, sCD52, which is increased in visceral adipose tissue in obesity, suppresses the inflammatory activity of macrophages/Kupffer cells in the liver, thereby attenuating hepatic steatosis and improving glucose metabolism.
- |||||||||| fingolimod / Generic mfg.
Review, Journal: Cryptococcosis Associated With Biologic Therapy: A Narrative Review. (Pubmed Central) - Jul 1, 2024
antagonists, Bruton tyrosine kinase inhibitors, fingolimod, JAK/STAT inhibitors (Janus kinase/signal transducer and activator of transcription), and monoclonal antibody against CD52. Other risk factors-such as age, underlying condition, and concurrent immunosuppressants, especially corticosteroids-should also be taken into account during risk stratification.
- |||||||||| Biomarker, Journal: CD52/FLAG and CD52/HA Fusion Proteins as Novel Magnetic Cell Selection Markers. (Pubmed Central) - Jun 27, 2024
The results of this study demonstrate that the surface markers CD52/FLAG and CD52/HA can be effectively used for magnetic cell selection, and their efficiencies are comparable to that of the commonly used LNGFR marker. At the same time, the significant advantage of these markers is the absence of HA and FLAG epitope sequences in cellular proteins, which rules out the spurious co-isolation of negative cells.
- |||||||||| Journal: A Novel Macrophage Subpopulation Conveys Increased Genetic Risk of Coronary Artery Disease. (Pubmed Central) - Jun 20, 2024
Our results provide genetic evidence of the divergent roles of macrophage subsets in atherogenesis and highlight lipid-handling macrophages as a key subpopulation through which genetic variants operate to influence disease. These findings provide an unbiased framework for functional fine-mapping of genome-wide association study results using single-cell multiomics and offer new insights into the genotype-environment interactions underlying atherosclerotic disease.
- |||||||||| Rituxan (rituximab) / Roche
THE CD19-CAR COSTIMULATORY DOMAINS DIFFERENTLY AFFECT RESISTANCE DEVELOPMENT IN B-ALL AND B-CELL LYMPHOMA. (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_3863;
Our in vitro models can mirror diverse scenarios encountered in patients andmay be used to better understand the biology of 4-1BB- and CD28-based clinical CAR products. Furthermore,our results open the door for discussion about the significance of antibody clones used for the detection ofCD19 epitopes in patients treated with CD19 CAR-T therapies.
- |||||||||| Campath (alemtuzumab) / Sanofi
CHARACTERIZATION OF CD38 EXPRESSION IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) PATIENTS: A SINGLE-CENTER EXPERIENCE OF 20 CASES (Poster Area (Hall 7)) - May 15, 2024 - Abstract #EHA2024EHA_1614;
We provide new evidence regarding CD38 expression in T-PLL, identifying a CD38High group characterized byactivating STAT5B mutations and demonstrating that CD38 expression does not affect patients OS. This workexpands the therapeutic scenario for T-PLL, providing the rationale to evaluate immune-targeting of CD38 asan alternative strategy for the treatment of a discrete subgroup of T-PLL patients.
- |||||||||| Campath (alemtuzumab) / Sanofi
High Levels of Complement-Binding Donor-Specific AntiHLA Antibodies: Are They Always Pathogenic? () - May 12, 2024 - Abstract #EFI2024EFI_279;
He was induced with alemtuzumab (anti-CD52) and initiated on tacrolimus, mycophenolate mofetil, and rapid steroid withdrawal...The decision was made not to treat his DSA and to add prednisone (5.0 mg) to his immunosuppression...High levels of complement-binding DSA are not always associated with AMR. Our understanding of the pathogenicity and significance of DSA continues to evolve and requires further investigation.
|
